Chugai Pharmaceutical Co., Ltd. is a corporation located at 5-5-1 Ukima, Kita-ku, Tokyo, where Okuda Osamu, the CEO and CEO, was established on March 8, 1943 (corporate number: 5011501002900). The final registration was updated on October 5, 2015, and a new establishment (registration of a corporate number) was carried out.
Trademarks such as SMART-Fc, ALE, TRAB are registered. White company information is currently being posted.
The financial results for the fiscal year ending December 2024 (revenue: 1.170.611 trillion yen, net income: 387.317 billion yen) . Employees and former employees rated the review site on various job change meetings with a score of 3.8/5.0 and Kaisha's reputation with a score of 75/100.
There is no legal violation/disposition/black information posted.
Company Profile
Corporate number | 5011501002900 |
---|---|
Corporate name | Chugai Pharmaceutical Co., Ltd. |
Furigana | Chugai Seiyaku |
Business overview | Manufacturing and sales of medical drugs |
Address/Map | 〒115-0051 5-5-1 Ukima, Kita-ku, Tokyo |
Stock code | 4519 |
President/Representative | President and CEO Okuda Okuda Senior Executive Officer CFO Taniguchi Iwaaki Senior Executive Officer Iikura Jin |
URL | https://www.chugai-pharm.co.jp/ |
telephone number | Phone number: 03-3281-6611 Fax number: 03-3281-2828 |
Establishment | March 8, 1943 |
Number of employees | 7,778 people (consolidated) *As of December 31, 2024 |
Industry | Medical/welfare |
Corporate number designation date | 2015/10/05 *Corporate numbers for corporations established before 2015/10/05 are uniformly designated as 2015/10/05. |
Last registration update date | 2015/10/05 |
Press releases and advertisements from Chugai Pharmaceutical Co., Ltd.
Currently, there are no press release articles from Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. financial history (million yen)
year | quarter | Submission date | sales revenue | Operating profit | Net income | Comprehensive income for the period |
---|---|---|---|---|---|---|
Consolidated for December 2012 | 3Q results | 2013/10/25 | 275,591 | 50,848 | 30,738 | 31,999 |
Full-year results | 2014/01/30 | 386,552 | 74,663 | 46,052 | 52,488 | |
Consolidated for December 2013 | 1Q results | 2014/04/24 | 90,416 | 14,663 | 8,897 | 11,965 |
2Q results | 2014/07/24 | 201,016 | 38,120 | 24,748 | 30,298 | |
3Q results | 2013/10/25 | 306,533 | 58,160 | 38,164 | 45,746 | |
Full-year results | 2014/01/30 | 423,652 | 78,738 | 50,895 | 66,793 | |
Consolidated for December 2014 | 1Q results | 2014/04/24 | 124,045 | 31,089 | 18,776 | 16,727 |
2Q results | 2014/07/24 | 222,022 | 43,117 | 28,897 | 24,997 | |
3Q results | 2014/10/24 | 333,426 | 59,134 | 39,730 | 34,857 | |
Full-year results | 2015/01/28 | 461,109 | 75,859 | 50,980 | 48,485 | |
Consolidated for December 2015 | 1Q results | 2015/04/22 | 117,083 | 20,750 | 14,582 | 11,460 |
2Q results | 2015/07/23 | 240,178 | 43,210 | 30,137 | 30,299 | |
3Q results | 2015/10/22 | 367,772 | 67,059 | 47,647 | 45,480 | |
Full-year results | 2016/01/28 | 498,839 | 86,784 | 61,125 | 57,476 | |
Consolidated for December 2016 | 1Q results | 2016/04/22 | 119,893 | 20,053 | 14,500 | 10,113 |
2Q results | 2016/07/21 | 247,531 | 43,513 | 31,549 | 20,122 | |
3Q results | 2016/10/25 | 361,517 | 58,635 | 43,084 | 35,980 | |
Full-year results | 2017/02/01 | 491,780 | 76,884 | 53,592 | 51,073 | |
Consolidated for December 2017 | 1Q results | 2017/04/25 | 125,467 | 26,345 | 18,500 | 15,467 |
2Q results | 2017/07/27 | 252,774 | 47,101 | 36,100 | 36,130 | |
3Q results | 2017/10/25 | 387,645 | 76,233 | 57,196 | 58,177 | |
Full-year results | 2018/02/01 | 534,199 | 98,934 | 72,713 | 76,081 | |
Consolidated for December 2018 | 1Q results | 2018/04/24 | 147,427 | 38,362 | 27,888 | 25,613 |
2Q results | 2018/07/26 | 285,123 | 66,569 | 48,672 | 46,292 | |
3Q results | 2018/10/24 | 426,440 | 97,912 | 70,340 | 70,856 | |
Full-year results | 2019/01/31 | 579,787 | 124,323 | 92,488 | 87,587 | |
Consolidated for December 2019 | 1Q results | 2019/04/24 | 154,288 | 46,094 | 35,031 | 35,456 |
2Q results | 2019/07/25 | 320,285 | 95,052 | 69,254 | 67,553 | |
3Q results | 2019/10/24 | 508,851 | 160,878 | 117,395 | 114,588 | |
Full-year results | 2020/01/30 | 686,184 | 210,597 | 157,560 | 155,127 | |
Consolidated for December 2020 | 1Q results | 2020/04/23 | 179,424 | 72,411 | 51,533 | 50,138 |
2Q results | 2020/07/27 | 368,120 | 140,629 | 102,293 | 101,835 | |
3Q results | 2020/10/22 | 576,520 | 227,318 | 162,425 | 162,150 | |
Full-year results | 2021/02/04 | 786,946 | 301,230 | 214,733 | 216,748 | |
ending December 2021 | 1Q results | 2021/04/22 | 168,817 | 63,967 | 47,411 | 51,688 |
2Q results | 2021/07/26 | 390,229 | 160,679 | 118,137 | 120,997 | |
3Q results | 2021/10/22 | 677,493 | 282,835 | 204,154 | 208,791 | |
Full-year results | 2022/02/03 | 999,759 | 421,897 | 302,995 | 306,020 | |
ending December 2022 | 1Q results | 2022/04/25 | 360,554 | 187,007 | 131,775 | 127,822 |
2Q results | 2022/07/21 | 596,166 | 286,947 | 204,153 | 194,538 | |
3Q results | 2022/10/24 | 821,450 | 383,835 | 271,950 | 258,250 | |
Full-year results | 2023/02/02 | 1,259,946 | 533,309 | 374,429 | 373,935 | |
ending December 2023 | 1Q results | 2023/04/27 | 312,240 | 98,296 | 73,500 | 78,149 |
2Q results | 2023/07/27 | 579,657 | 210,910 | 156,693 | 154,432 | |
3Q results | 2023/10/24 | 837,555 | 317,598 | 234,266 | 241,810 | |
Full-year results | 2024/02/01 | 1,111,367 | 439,174 | 325,472 | 332,256 | |
ending December 2024 | 1Q results | 2024/04/24 | 236,949 | 99,874 | 74,401 | 82,114 |
2Q results | 2024/07/25 | 552,860 | 258,195 | 186,262 | 191,645 | |
3Q results | 2024/10/25 | 868,538 | 418,602 | 295,758 | 308,636 | |
Full-year results | 2025/01/30 | 1,170,611 | 542,002 | 387,317 | 408,655 | |
year | quarter | Submission date | sales revenue | Operating profit | Net income | Comprehensive income for the period |